| Identification | Back Directory | [Name]
Minesapride | [CAS]
1184662-54-1 | [Synonyms]
Minesapride, 10 mM in DMSO
Benzamide, 4-amino-5-chloro-N-[[(2S)-4-[[1-(2-hydroxyacetyl)-4-piperidinyl]methyl]-2-morpholinyl]methyl]-2-methoxy- | [Molecular Formula]
C21H31ClN4O5 | [MOL File]
1184662-54-1.mol | [Molecular Weight]
454.95 |
| Hazard Information | Back Directory | [Uses]
Minesapride is a partial agonist with a highly selective serotonin 4 (5-HT4) receptor. Minesapride enhances gastrointestinal peristalsis and colon transport by activating the 5-HT4 receptor. Minesapride increases bowel movements and suppresses visceral allergic reactions. Minesapride can be used in the study of constipation-type irritable bowel syndrome (IBS-C)[1]. | [References]
[1] Fukudo S, et al. Efficacy and safety of 5-HT4 receptor agonist minesapride for irritable bowel syndrome with constipation in a randomized controlled trial[J]. Clinical Gastroenterology and Hepatology, 2021, 19(3): 538-546. e8. DOI:10.1016/j.cgh.2020.03.019 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|